Outpatient management of febrile neutropenia: Is it safe yet?

Journal of Supportive Oncology

Volumn 6, Issue 5, 2008, Pages 219-220

  Johnson, Tami N ^a   De Jesus, Yvette A ^a   McMahon, Leslie ^a   Rolston, Kenneth V I ^a   Row, Margaret B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT;

ANTIBIOTIC SENSITIVITY; CALORIC INTAKE; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; EARLY DIAGNOSIS; FEBRILE NEUTROPENIA; HEALTH CARE COST; HEALTH CARE DELIVERY; HIGH RISK PATIENT; HOSPITAL CARE; HUMAN; MUCOSA INFLAMMATION; NEUTROPHIL COUNT; NOTE; OUTPATIENT CARE; PATIENT CARE; PATIENT MONITORING; PATIENT SAFETY; RISK ASSESSMENT;

AMBULATORY CARE; ANTINEOPLASTIC AGENTS; FEVER; HUMANS; NEUTROPENIA;

EID: 45249098030     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (9)

1. Malik IA, Khan WA, Karim M, Aziz Z, Khan MA. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995;98:224-231. [7872337]
2. Elting LS, Lu C, Escalante CP, et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 2008;26:606-611. [18235119]
3. Talcott JA, Friberg R, Mayer RJ, Goldman L.The medical course of cancer patients with fever and neutropenia:clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988;148:2561-2568. [3196123]
4. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk-index: a multinational scoring system to predict low-risk febrile neutropenic patients. J Clin Oncol 2000;18:3038-3051. [10944139]
5. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Myeloid Growth Factors. Version 1.2008. Available at: http://www.nccn.org/professionals/physician_gls/recently_updated.asp. Accessed April 24, 2008.
6. Escalante CP, Weiser MA, Manzullo E, et al. Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Support Care Cancer 2004;12:657-662. [15185134]
7. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections. Version 1.2008. Available at:http://www.nccn.org/professionals/physician_gls/ recently_updated.asp. Accessed April 22, 2008.
8. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751. [11850858]
9. Rolston KV. Management of infections in the neutropenic patient. Annu Rev Med 2004;55:519-526. [1476534]